Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

← catalyst calendar

NCT06327815

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
633actual
Sites
35
Country
China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-03-15actualWhen the study began enrolling
Primary completion2025-06-30actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-06-30actualThe whole study's end, after follow-up
First posted2024-03-25actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-10-31actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • Drug: Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets — also filed as FDC Regimen of Dapagliflozin/Metformin XR
  • Drug: Dapagliflozin tablets and Metformin HCl extended-release tablets — also filed as Co-administered Dual Therapy

Primary outcome

what the primary-completion date above is the date OF
Change in HbA1c from baseline
measured 24 weeks

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed